Why the study?
Distinguishing between intravascular and tissue congestion to guide personalized treatment in acute heart failure remains challenging.
Does CA125 monitoring improve the clinical management and phenotyping of congestive heart failure?
Does CA125 monitoring improve the clinical management and phenotyping of congestive heart failure?
Answers are grounded in this paper and cite their sources.
CA125 shows promise as a sensitive biomarker for tissue congestion and right heart function in patients with congestive heart failure.
Congestion is the permanent mechanism driving disease progression in patients with acute heart failure (AHF) and also is an important treatment target. However, distinguishing between the two different phenotypes (intravascular congestion and tissue congestion) for personalized treatment remains challenging. Historically, carbohydrate antigen 125 (CA125) has been a frequently used biomarker for the screening, diagnosis, and prognosis of ovarian cancer. Interestingly, CA125 is highly sensitive to tissue congestion and shows potential for clinical monitoring and optimal treatment of congestive heart failure (HF). Furthermore, in terms of right heart function parameters, CA125 levels are more advantageous than other biomarkers of HF. CA125 is expected to become a new biological alternative marker for congestive HF and thereby is expected be widely used in clinical practice.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: